Does spironolactone reduce markers of cardiac fibrosis synthesis and improve outcomes in patients with congestive heart failure?
Patients with congestive heart failure (CHF)
Spironolactone
Serum levels of markers of cardiac fibrosis synthesis and clinical outcomesurrogate
The survival benefit of spironolactone in congestive heart failure may be partly mediated by limiting excessive extracellular matrix turnover and cardiac fibrosis.
In patients with CHF, high baseline serum levels of markers of cardiac fibrosis synthesis are significantly associated with poor outcome and decrease during spironolactone therapy. The benefit from spironolactone was associated with higher levels of collagen synthesis markers. These results suggest that limitation of the excessive extracellular matrix turnover may be one of the various extrarenal mechanisms contributing to the beneficial effect of spironolactone in patients with CHF.
Building similarity graph...
Analyzing shared references across papers
Loading...
Faı̈ez Zannad
François Alla
B. Dousset
Circulation
Monsanto (United States)
Building similarity graph...
Analyzing shared references across papers
Loading...
Zannad et al. (Tue,) studied this question.
www.synapsesocial.com/papers/69af0aefe03f6d79082a8c70 — DOI: https://doi.org/10.1161/01.cir.102.22.2700
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: